Personalized mRNA Cancer Vaccine Cuts Melanoma Relapse or Death Risk by 42 Percent in Large Trial
Moderna and MSD report a 42 percent relative reduction in relapse or death for melanoma patients given a tailored mRNA therapy plus Keytruda, according to BILD.
Oct 23, 2026 · 3 min read
208 views